PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is indicated as a source of water and electrolytes or as an alkalinizing agent.
PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is compatible with blood or blood components. It may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. PLASMA-LYTE A Injection and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components.
Published Studies Related to Plasma-Lyte 148 (Multiple Electrolytes Injection)
Overview of the study protocols and statistical analysis plan for the Saline
versus Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program. 
Intravenous Fluid Therapy (SPLIT) research program... CONCLUSION: The SPLIT study program will provide preliminary data on
The energetic and metabolic effect of Ringerfundin (B. Braun) infusion and comparison with Plasma-Lyte (Baxter) in healthy volunteers. 
Measurement of parameters of energy requirement, respiratory quotient (RQ), rate of oxygen consumption (VO2) and rate of carbon dioxide production (VCO2) reveal Ringerfundin as an excellent and metabolically stable-acting balanced ionic solution, which does not increase the consumption of O2 or the total energy requirement.
Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study. [2008.11]
Fluid-induced metabolic acidosis can be harmful and can complicate cardiopulmonary bypass. In an attempt to prevent this disturbance, we designed a bicarbonate-based crystalloid circuit prime balanced on physico-chemical principles with a strong ion difference of 24 mEq/l and compared its acid-base effects with those of Plasma-Lyte 148, a multiple electrolyte replacement solution containing acetate plus gluconate totalling 50 mEq/l...
A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid
therapy (SPLIT) study. 
Fluid Therapy (SPLIT) study... CONCLUSION: The SPLIT study started on 1 April 2014 and will provide
Plasma acetate, gluconate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte 148 with a bicarbonate-balanced solution. 
INTRODUCTION: As even small concentrations of acetate in the plasma result in pro-inflammatory and cardiotoxic effects, it has been removed from renal replacement fluids. However, Plasma-Lyte 148 (Plasma-Lyte), an electrolyte replacement solution containing acetate plus gluconate is a common circuit prime for cardio-pulmonary bypass (CPB). No published data exist on the peak plasma acetate and gluconate concentrations resulting from the use of Plasma-Lyte 148 during CPB... CONCLUSIONS: Use of acetate containing prime solutions result in supraphysiological plasma concentrations of acetate. The use of acetate-free prime fluid in CPB significantly reduced but did not eliminate large acetate surges in cardiac surgical patients. Complete elimination of acetate surges would require the use of acetate free bolus fluids and cardioplegia solutions. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000267055.
Clinical Trials Related to Plasma-Lyte 148 (Multiple Electrolytes Injection)
Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients [Not yet recruiting]
The purpose of this study is to determine whether an intravenous salt solution called
"Plasmalyte" causes less abnormality of the body's acid levels than a solution called
Allogeneic Mesenchymal Stem Cells in Osteoarthritis [Recruiting]
This trial is planed to study if allogeneic mesenchymal stem cells would be safe and
beneficial in osteoarthritis of knee joint. This is a double blind study. Different doses of
stem cells will be used in this study.
Allogeneic Mesenchymal Stem Cells for Osteoarthritis [Recruiting]
This study is designed to know the safety and efficacy of 2 different doses of mesenchymal
stem cells in patients suffering from osteoarthritis of knee joint.
Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery [Not yet recruiting]
Study goal: This study will examine whether there is a significant difference in
postoperative outcomes between GDFT using a colloid solution versus a crystalloid solution.
Hypothesis: Perioperative fluid optimization through the use of a closed-loop assistance
with a balanced starch solution (volulyteŽ) will be associated with a decrease in
postoperative complications compared to the same approach using a balanced crystalloid
Objective: To establish which kind of intravenous fluid used for goal directed therapy with
closed-loop assistance will reduce the number of postoperative complications (evaluation
made by the POMS score).
Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach [Recruiting]
The purpose of this study is to conduct a prospective, randomized, controlled trial
comparing a restrictive vs. conservative fluid strategy in thoracic surgery patients.
Excessive perioperative fluid has been retrospectively implicated in the development
postoperative acute lung injury (PALI) and pulmonary edema following lung resection.
However, fluid restriction in these patients is not without risk and may compromise end
organ perfusion (i. e. acute kidney injury). The hypothesis is that a conservative fluid
approach in thoracic surgery patients will result in better end organ perfusion with fewer
occasions of acute kidney injury (AKI) without causing an increase in postoperative acute
lung injury or pulmonary edema.